Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 11, 2009, Pages 5259-5265

  Ooi, Yen Hoong ^a   Oh, Dong Jin ^a   Rhee, Douglas J ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; COLLAGENASE 1; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; LATANOPROST; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 24; PROSTAGLANDIN DERIVATIVE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; UNOPROSTONE;

ARTICLE; CELL LYSATE; CILIARY BODY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SMOOTH MUSCLE FIBER; ZYMOGRAPHY;

AMIDES; ANTIHYPERTENSIVE AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; CILIARY BODY; CLOPROSTENOL; DINOPROST; HUMANS; INTRAOCULAR PRESSURE; MATRIX METALLOPROTEINASES; MUSCLE, SMOOTH; PROSTAGLANDINS F, SYNTHETIC; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 74049146669     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3356     Document Type: Article

References (76)

1. Barany EH, Rohen JW. Localized contraction and relaxation within the ciliary muscle of the vervet monkey (Cercopithecus ethiops), In: Rohen JW, ed. The Structure of the Eye, Second Symposium. Stuttgart, Germany: FK Schattauer Verlag; 1965:287-311.
2. Bill A. Effects of atropine and pilocarpine on aqueous humour dynamics in cynomolgus monkeys (Macaca irus). Exp Eye Res. 1967;6:120-125.
3. Townsend DJ, Brubaker RF. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest Ophthalmol Vis Sci. 1980;19:256-266.
4. Schenker JI, Yablonski ME, Podos SM, Linder L. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol. 1981;99:1212-1216.
5. Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2α. Exp Eye Res. 1988;47:761-769.
6. Lütjen-Drecoll E, Tamm E. The effects of ocular hypotensive doses of PGF F2α-1-isopropylester on anterior segment morphology. In: Bito LZ, Stjernschantz J, eds. The ocular effects of prostaglandins and other eicosanoids. New York: Allan R. Liss, Inc. 1989:737-776.
7. Weinreb RN, Kashiwagi K, Kashiwagi F, Tuskahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997; 38:2772-2780.
8. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179-191.
9. El-Shabrawi Y, Eckhardt M, Berghold A, et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye. 2000;14:375-383.
10. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15:869-875.
11. Anthony TL, Lindsey JD, Weinreb RN. Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest Ophthalmol Vis Sci. 2002;43:3705-3711.
12. Oh DJ, Martin JL, Williams AJ, et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body following latanoprost. Invest Ophthalmol Vis Sci. 2006;47:953-963.
13. Butler GS Will H Atkinson SJ, Murphy G. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem. 1997;244:653-657.
14. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A; a kinetic study. J Biol Chem. 1998;273:871-880.
15. Khasigov PZ, Podobed OV, Gracheva TS, Salbiev KD, Grachev SV, Berezov TT. Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Biochemistry (Mosc). 2003;68: 711-717.
16. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10:8229-8234.
17. Zhou X, Hovell CJ, Pawley S, et al. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrinolysis. Liver Int. 2004;24:492-501.
18. Maata M, Tervahartiala T, Harju M, Airaksinen J, Autio-Harmainen H, Sorsa T. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. J Glaucoma. 2005;14:64-69.
19. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005;241:92-101.
20. Ahmed Z, Dent RG, Leadbeater WE, Smith C, Berry M, Logan A. Matrix metalloproteinases: degredation of the inhibitory environment of the transected optic nerve and the scar by regenerating axons. Mol Cell Neurosci. 2005;28:64-78.
21. Pauschinger M, Chandrasekharan K, Schultheiss JP. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev. 2004;9:21-31.
22. Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the Cynomolgus monkey. Exp Eye Res. 1989;48:707-716.
23. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenburgh AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131:19-24.
24. Sakurai M, Araie M, Oshika T, et al. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 1991;35:156-165.
25. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. Ophthalmology. 2008;115:790-795.
26. Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005;46:4159-4163.
27. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19:501-515.
28. Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari HR, Abdel-Latif AA. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther. 2003;19:437-455.
29. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003;44:715-721.
30. Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002;18:313-324.
31. Susanna R Jr, Medeiros FA, Vessani RM, Giampani J Jr, Borges AS, Jordao ML. Intraocular pressure fluctuations in response to the water-drinking provocative test in patients using latanoprost versus unoprostone. J Ocul Pharmacol Ther. 2004;20:401-410.
32. Takahashi I, Tanaka M. Switching to latanoprost monotherapy for 24 weeks in glaucoma patients. Eur J Ophthalmol. 2004;14:401-406.
33. Tsukamoto H, Mishima HK, Kitazawa Y, Araie M, Abe H, Negi A. Glaucoma Study Group. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension. J Glaucoma. 2002;11:497-501.
34. Jampel HD, Bacharach J, Sheu WP, Wohl LG, Solish AM, Christie W. Latanoprost/Unoprostone Study Group. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol. 2002;134:863-871.
35. Sponsel WE, Paris G, Trigo Y, Pena M. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. Am J Ophthalmol. 2002;134:552-559.
36. Aung T, Chew PT, Oen FT, et al. Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure (published correction in Br J Ophthalmol. 2002;86:707). Br J Ophthalmol. 2002;86:75-79.
37. Susanna R Jr, Giampani J Jr, Borges AS, Vessani RM, Jordao ML. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001;108:259-263.
38. Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther. 2004;21:247-262.
39. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135: 55-63.
40. Parrish RK, Palmberg P, Sheu WP. XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
41. Weinreb RN, Kim D-M, Lindsey JD. Propagation of ciliary smooth muscle cells in vitro and effects of prostaglandin F2α on calcium efflux. Invest Ophthalmol Vis Sci. 1992;33:2679-2686.
42. Rhee DJ, Tamm ER, Russell P. Donor corneoscleral buttons: a new source of trabecular meshwork for research. Exp Eye Res. 2003; 77:749-756.
43. Camras CB, Toris CB, Sjoquist B, et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology. 2004; 111:2193-2198.
44. Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(suppl 1):S6-S12.
45. Numaga J, Koseki N, Kaburaki T, Kawashima H, Tomita G, Araie M. Intraocular metabolites of isopropyl unoprostone. Curr Eye Res. 2005;30:909-913.
46. Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:3887-3895.
47. Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:716-717.
48. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
49. Camras CB, Hedman K. US Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003;12:466-469.
50. Cantor LB, Hoop J, Morgan L, WuDunn D, Catoira Y. the bimatoprost-travoprost study group: intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006;90: 1370-1373.
51. Nagase H, Suzuki K, Morodomi T. Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl. 1992;1:237-244.
52. Wang N, Lindsey JD, Angert M. Latanoprost and matrix metalloproteinase-1 in human choroid organ cultures. Curr Eye Res. 2001;22(3):198-207.
53. Hinz B, Rösch S, Ramer R. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J. 2005;19(13):1929-1931.
54. Mathisen B, Loennechen T, Gedde-Dahl T. Fibroblast heterogeneity in collagenolytic response to colchicines. Biochem Pharmacol. 2006;71(5):574-583.
55. Yu WH, Woessner JF Jr. Heparin-enhanced zymographic detection of matrilysin and collagenases. Anal Biochem. 2001;293(1):38-42.
56. Ciccocioppo R, Di Sabatino A, Bauer M. Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest. 2005;85(3):397-407.
57. Zong W, Zyczynski HM, Meyn LA. Regulation of MMP-1 by sex steroid hormones in fibroblasts derived from the female pelvic floor. Am J Obstet Gynecol. 2007;196(4):349.e1-e11.
58. Qian LW, Xie J, Ye F. Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol. 2007;81(13):7001-7010.
59. Fernández-Resa P, Mira E, Quesada AR. Enhanced detection of casein zymography of matrix metalloproteinases. Anal Biochem. 1995;224(1):434-435.
60. Manicourt DH, Lefebvre V. An assay for matrix metalloproteinases and other proteases acting on proteoglycans, casein, or gelatin. Anal Biochem. 1993;215(2):171-179.
61. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr. TIMP-3 binds to sulphated glycosaminoglycans of the extracellular matrix. J Biol Chem. 2000;275:31226-31232.
62. Pavloff N, Staskus PW, Kishnani NS, Hawkes SP. A new inhibitor of metalloproteinases from chicken: ChIMP-3: a third member of the TIMP family. J Biol Chem. 1992;267:17321-17326.
63. Yang TT, Hawkes SP. Role of the 21-kDa protein TIMP-3 in oncogenic transformation of culture chicken embryo fibroblasts. Proc Natl Acad Sci USA. 1992;89:10676-10680.
64. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAMTS5). J Biol Chem. 2001;276:12501-12504.
65. Nagase H, Brew K. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem Soc Symp. 2003;70:201-212.
66. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998;435:39-44.
67. Liu YE, Wang M, Greene J, et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem. 1997;272:20479-20483.
68. Sharif NA, Kaddour-Djebbar I, Abdel-Latif AA. Cat iris sphincter smooth-muscle contraction: comparison of FP-class prostaglandin analog agonist activities. J Ocul Pharmacol Ther. 2008;24:152-163.
69. Sharif NA. Synthetic F. P-prostaglandin-induced contraction of rat uterus smooth muscle in vitro. Prostaglandins Leukot Essent Fatty Acids. 2008;78:199-207.
70. Enoki M, Saito J, Hara M, Uchida T, Sagara T, Nishida T. Additional reduction in intraocular pressure achieved with latanoprost in normal-tension glaucoma patients previously treated with unoprostone. Jpn J Ophthalmol. 2006;50(4):334-337.
71. Aung T, Chew PT, Yip CC, et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001;131(5):636-642.
72. Tsukamoto H, Mishima HK, Kitazawa Y, Araie M, Abe H, Negi A. Glaucoma Study Group. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension. J Glaucoma. 2002;11(6):497-501.
73. Kobayashi H, Kobayashi K, Okinami S. A comparison of intraocular pressure-lowering effect of prostaglandin F2 -alpha analogues, latanoprost, and unoprostone isopropyl. J Glaucoma. 2001;10(6): 487-492.
74. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135(1): 55-63.
75. Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006;23(3):385-394.
76. Choplin N, Bernstein P, Batoosingh AL, Whitcup SM. Bimatoprost/Latanoprost Study Group. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol. 2004;49(Suppl 1):S19-S25.